Neurology Advisor interviews Aleksandra M. Kwasnik, MD, who co-authored a recent review on cannabinoids that was published in Current Pulmonology Reports.

The evidence available thus far shows some promise for future use of cannabinoid compounds for primary or adjunctive treatment of sleep disorders, such as sleep-disordered breathing, insomnia, and restless legs syndrome. I do caution that the research for this particular indication is in its infancy, and it remains difficult to generalize available data.

For example, the PACE trial, which evaluated the use of the synthetic cannabinoid dronabinol in the treatment of OSA, was conducted as a phase 2 trial and may soon be expanded to include more efficacy data.